Clinical Trials Logo
  1. Home
  2. H. Pylori Infection
  3. NCT02767479

Comparison of Rabeprazole and Esomperazole for the Eradication of H. Pylori

H. Pylori Infection Clinical Trial

Official title:
Comparison of Rabeprazole and Esomperazole for the Eradication of H. Pylori (CREATION Study)

Clinical Trial Summary

Patients infected with H. pylori are treated with rabeprazole 10 mg bid, AMPC 750 mg bid and CAM 200 mg bid or esomeprazole 20 mg bid, AMPC 750 mg bid and CAM 200 mg bid. Eradication rates are compared. Patients who have ever failed in eradication by CAM-based regimen are treated with rabeprazole 10 mg bid, AMPC 750 mg bid and MNZ 250 mg bid or esomeprazole 20 mg bid, AMPC 750 mg bid and MNZ 250 mg bid.

Clinical Trial Description

Patients infected with H. pylori are treated with rabeprazole 10 mg bid, AMPC 750 mg bid and CAM 200 mg bid or esomeprazole 20 mg bid, AMPC 750 mg bid and CAM 200 mg bid. Eradication rates are compared. Patients who have ever failed in eradication by CAM-based regimen are treated with rabeprazole 10 mg bid, AMPC 750 mg bid and MNZ 250 mg bid or esomeprazole 20 mg bid, AMPC 750 mg bid and MNZ 250 mg bid. CYP2C19 genotypes and susceptibility to CAM are genetically measured. Other factors are also analyzed with reference to eradication rates. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02767479
Study type Interventional
Source Hamamatsu University
Contact
Status Completed
Phase Phase 3
Start date July 2012
Completion date April 2016
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06045494 - The Efficacy of Treatment for Helicobacter Pylori Infection in Preschooler by Yoghurt With LG21 N/A
Not yet recruiting NCT01449500 - Supplementation With L. Reuteri in H. Pylori Infected Adults N/A
Completed NCT01234389 - Immediate Detection of Helicobacter Infection With a New Electrochemical System. N/A
Not yet recruiting NCT05387005 - Screening Strategy for Gastric Cancer Prevention N/A
Not yet recruiting NCT02761005 - Eradication of H. Pylori Therapy Individualized by the Mutation of 23S rRNA of H. Pylori Phase 2
Recruiting NCT03142620 - Effect of Vitamin D on Drug Resistant Helicobacter Pylori (HP) Eradication Study Phase 3
Withdrawn NCT02090738 - A Randomized, Open-label Study on Helicobacter Pylori Eradication With Standard Triple Regimen Plus Acetazolamide Phase 2
Recruiting NCT01335334 - H. Pylori Eradication Using Pyklear in Adults in El Paso, Texas: a Pilot Study Phase 4
Recruiting NCT05544396 - Study on the Probiotics Regulating miRNA in H. Pylori-induced Wnt/β-catenin Gastric Carcinogenesis. N/A
Recruiting NCT04713670 - Comparison of Vonoprazan-based Versus Lansoprazole-based Triple Therapy, High Dose Dual Therapy, Bismuth and Non-bismuth Quadruple Therapy in the First-line Treatment of Helicobacter Pylori Infection Phase 4
Recruiting NCT06045832 - Oral Helicobacter Pylori Eradication N/A
Completed NCT05453994 - Bismuth for PCAB-based H. Pylori Eradication
Recruiting NCT02328131 - European Registry on the Management of Helicobacter Pylori Infection
Completed NCT00197457 - Pepsinogens as the Early Marker of H. Pylori Eradication Phase 2
Completed NCT04036838 - ARJ C13 Urea Breath Test System Phase 2
Completed NCT06050824 - A Comparative Study Between Concomitant Versus Load Therapy in Eradication of Helicobacter Pylori Infection Phase 4
Completed NCT01505127 - Efficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradication of H. Pylori Phase 3
Recruiting NCT05176821 - Eradication Efficacy and Safety of Two Rescue Treatments for Helicobacter Pylori Infection N/A
Completed NCT05002595 - H. Pylori Treatment Between Modified Quadruple Regimen and Tailored Therapy
Recruiting NCT03597672 - Early Detection and Screening Strategy of Gatric Cancer in Sichuan Province-A Prospective Cohort Study (WCH-GC-SIGES-01)